WO1999047174A1 - Amorphous glasses for stabilising sensitive products - Google Patents

Amorphous glasses for stabilising sensitive products Download PDF

Info

Publication number
WO1999047174A1
WO1999047174A1 PCT/GB1999/000820 GB9900820W WO9947174A1 WO 1999047174 A1 WO1999047174 A1 WO 1999047174A1 GB 9900820 W GB9900820 W GB 9900820W WO 9947174 A1 WO9947174 A1 WO 9947174A1
Authority
WO
WIPO (PCT)
Prior art keywords
mannitol
drying
glass
compound
inositol
Prior art date
Application number
PCT/GB1999/000820
Other languages
French (fr)
Inventor
Peter Ronai
Bruce Joseph Roser
Arcadio Garcia De Castro
Original Assignee
Cambridge Biostability Limited
Bruce Joseph Roser
Arcadio Garcia De Castro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805699.7A external-priority patent/GB9805699D0/en
Priority claimed from GBGB9820689.9A external-priority patent/GB9820689D0/en
Application filed by Cambridge Biostability Limited, Bruce Joseph Roser, Arcadio Garcia De Castro filed Critical Cambridge Biostability Limited
Priority to AU29451/99A priority Critical patent/AU2945199A/en
Priority to EP99910516A priority patent/EP1071465A1/en
Publication of WO1999047174A1 publication Critical patent/WO1999047174A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/37Sugar alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • trehalose Because it is subsequently degraded in the body by the specific enzyme, trehalase, to two molecules of glucose, trehalose possesses many of the properties of the ideal industrial stabiliser for foods and medical products.
  • a large scientific and patent literature has now developed on trehalose stabilisation of foods, vaccines, diagnostics and drugs.
  • the disadvantages of trehalose are that it is as yet not approved by the regulatory authorities, it is expensive and it contains contaminating reducing sugars, especially glucose, in all but the most rigorously purified material.
  • the effect of these substances is dose dependent and below a threshold concentration they do not work.
  • the substances useful in accordance with this invention promote the drying of mannitol solutions as glasses rather than crystals.
  • One of the most potent materials is the borate ion either as boric acid, or tetraborate salts of sodium or potassium. This probably forms a network complex with mannitol or even a covalent compound, sodium mannitoborate.
  • the quality of the glasses made by this process is high.
  • the glass transition temperature (Tg) of 1 :1 w/w mannitol/calcium lactate glass is around 68°C ( Figure 1). This compares with a Tg of around 90°C for a trehalose/sodium sulphate glass dried under the same conditions ( Figure 2). Both types of glass have Tg's well above any possible ambient storage temperature and, because the glasses are chemically inert and non-reactive, the entrapped products are stable at room temperatures and require no refrigeration of any kind.
  • Figure 1 shows differential scanning calorimetry of a 50 / 50 w/w mannitol / calcium lactate glass showing a clear glass transition at a temperature of 68 °C;
  • Figure 2 shows differential scanning calorimetry of a 50 / 50 w/w trehalose / calcium lactate glass showing a clear glass transition at a temperature of 90 °C;
  • Figure 3 shows the percentage recovery of alkaline phosphatase activity after vacuum- drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 6 weeks. There is no loss with formula 7 but serious losses with trehalose;
  • Figure 4 shows the percentage recovery of alkaline phosphatase activity after freeze-drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 7 weeks. There is little loss with either stabiliser;
  • Figure 5 shows the percentage recovery of Erythropoietin (EPO) after vacuum-drying in either trehalose or formula 8 containing mannitol, inositol, galactitol and calcium lactate followed by storage at 37°C or 50°C for up to 6 weeks. While there is serious losses with trehalose, no loss occurs with formula 8; and
  • Figure 6 shows the percentage recovery of EPO after freeze-drying in either trehalose or formula 7 containing mannitol, Inositol, galactitol and degraded gelatin (Byco C) or formula 8 in which calcium lactate was substituted for the gelatin. After storage at 37°C or 50°C for 7 weeks, there is no loss with any of the stabilising formulations.
  • Figure 7 shows the percentage recovery of alkaline phosphatase activity after spray drying formula 9 to which had been added insoluble calcium phosphate powder to increase the density of the glass microspheres. After storage at either 37°C or 55°C for up to 90 days there was no significant loss of activity.
  • Figure 8 shows the percentage recovery alkaline phosphatase activity after spray drying formula 1 1 to which had been added insoluble barium sulphate powder to increase the density of the glass microspheres. After storage at either 37"C or 55°C for up to 90 days there was again no significant loss of activity.
  • a network forming additive such as sodium or potassium tetraborate
  • a network forming additive such as sodium or potassium tetraborate
  • Affinity purified alkaline phosphatase from bovme intestinal mucosa (Sigma Chemical Co cat No p-8647) was vacuum-d ⁇ ed or freeze-d ⁇ ed m 200 ⁇ l volumes in formulation Number 7 above or in trehalose.
  • Vacuum drying was done at a shelf temperature of 40°C and a vacuum of 30- 100 milhtorr for 4 hr The temperature was then ramped gradually to 60°C over 1 hr and the vials were stoppered and removed from the vacuum chamber for high temperature storage trials Freeze-drying was done in a Labconco dryer at an initial shelf temperature of-40°C for 3 hr at a vacuum of 30-100 milhtorr The shelf temperature was then ramped to 0°C at 5°C / mm and held for 1 hr The shelf temperature was then raised to 40°C at 5°C / min and secondary drying was continued for a further 3 hr when the vials were stoppered under vacuum and removed for storage trials
  • EPO was vacuum dried or freeze-d ⁇ ed as above in the same solutions and also in a va ⁇ ant of formulation 7 in which calcium lactate was substituted for Byco C (Formula 8), and then subjected to the same stability tests before being assayed by a standard 2-s ⁇ te sandwich Enzyme Immunoassay
  • the fluorescent protein R-Phycoeryth ⁇ n was air-dried in trehalose, formula 3 or formula 4 on a hotplate as described in Example 1
  • the intensity of fluorescence was gauged visually when illuminated with a UV lamp.
  • the material dried in formula 3 was masked by an intense silver autofluorescence from the Byco C while the material dried in formula 4 fluoresced with the characteristic orange colour with apparently undimmished intensity

Abstract

Disclosed is a method of drying, without damage, a compound which is subject to deactivation on drying, or a mixture of such compounds, comprising subjecting an aqueous system containing the compound or mixture to drying in the presence of one or more monosaccharide sugar alcohols and at least one additive which is a glass-former or a glass-formation-facilitator, whereby the compound solidifies from solution as an amorphous glass rather than by forming crystals.

Description

AMORPHOUS GLASSES FOR STABILISING SENSITIVE PRODUCTS
Drying of biological molecules such as foodstuffs, vaccines and drugs is an ancient way of preserving them. However, the price that often has to be paid for increased stability is product damage and a decrease in quality. More recently it has been learned that certain additives can prevent this damage. Levine and Slade were amongst the first to realise that the best additives were substances that tended to solidify from solution as an amorphous glass rather than by forming crystals (Levine H and Slade L., Principles of cryostabilisation technology from structure/property relationships of carbohydrate/water systems: A review. Cryoletters 9 21-63 (1988)). Foremost amongst the stabilisers they recommended were certain sugars, notably sucrose. Although not formally proved, the stability of these dried formulations is assumed to be a function of the transformation of the sugar solution into a glass as it dries. As a consequence of the progressive increase in viscosity of the sugar syrup, it is thought that the active molecules are concentrated by a smooth progression from their mobile native state in liquid solution to an immobilised solid solution or glass. In the glass, molecular motion and hence diffusion-based molecular interactions are negligible. The chemistry responsible for degradation is arrested and the product remains stable as long as it remains dry and glassy (Franks F., Freeze drying: From empiricism to predictability. Cryoletters 11 93-110 (1990)).
The simple view that glass formation is the explanation for stability is incomplete. This explanation only holds for glasses that are inherently chemically unreactive and stable. It is incontrovertible that certain substances that form physically excellent glasses are nevertheless very poor stabilisers. Many of these are either chemically reactive, such as reducing sugars or are unstable, like sucrose or sorbitol and break down to reactive intermediates which degrade the product during storage in the dry state (Newman Y.M., Ring S.G. and Colaco C. The role of trehalose and other carbohydrates in biopreservation. Biotechnol. & Genet. Eng. Rev. 11 263-294 (1993)). A common reactivity of sugar glasses is the reducing action of the carbonyl group and the degradation products formed are often the familiar carbonyl-amine compounds of the Maillard reaction (Ellis G.P. The Maillard reaction. Adv. Carbohyd. Chem. 14 63-134 (1959)). Because the Maillard reaction is temperature dependent, it is only slowly progressive at low temperatures. Many glass-forming materials give excellent preservation of activity during the drying process itself but the product subsequently undergoes progressive deterioration unless stored under refrigeration.
The error of ignoring the subtle sugar chemistry that can proceed in dried preparations is widespread in the literature and has led to the advocacy of simple tests of the glass transition temperature of pure sugar solutions as a means of selecting good stabilisers. This approach has actually led to the recommendation of quite useless substances in the past (Franks F. Freeze drying: From empiricism to predictability Cryoletters 11 93-1 10 (1990)). In fact, the efficacy of a formulation is the result of multiple physical and chemical interactions between all the components in the formulation, including the active, on drying. All these interactions may not be predicted by current theories.
The superiority of the disaccharide trehalose as a stabiliser was first indicated by its prevalence in certain rare living creatures, which regularly dried out and could come back to life on rehydration. (Crowe J.H., Crowe L.M. and Chapman D. Preservation of membranes in anhydrobiotic organisms: The role of trehalose. Science 223 701 (1984)). In laboratory studies, trehalose incorporated into the buffer solutions from which active biomolecules were dried, resulted in a product with quite remarkable resistance to denaturation by heat (Colaco C.A.L.S., Sen S., Thangavelu M., Pinder S. and Roser B. Extraordinary stability of enzymes dried in trehalose: Simplified molecular biology. Biotechnol. 10. 1007-101 1 (1992)). Because it is subsequently degraded in the body by the specific enzyme, trehalase, to two molecules of glucose, trehalose possesses many of the properties of the ideal industrial stabiliser for foods and medical products. A large scientific and patent literature has now developed on trehalose stabilisation of foods, vaccines, diagnostics and drugs. The disadvantages of trehalose are that it is as yet not approved by the regulatory authorities, it is expensive and it contains contaminating reducing sugars, especially glucose, in all but the most rigorously purified material.
One of the alternative non-reducing and chemically stable sugar derivatives that might be expected to stabilise effectively is mannitol. Because of its remarkable resistance to water sorption at high atmospheric humidity (Wade A. and Weller P.J. Handbook of Pharmaceutical Excipients second edition p296 (1994)), it is widely used in tablet and powder formulations as a bulking and anti-caking agent. In combination with other excipients such as glycine, it is also widely used in freeze dried parenteral preparations but is added as a carrier to produce a stiff, homogeneous cake that improves the appearance of the lyophilised plug in a vial (Wade & Weller The Excipients Handbook 1994).
In published surveys of the stabilising ability of a wide range of sugars and sugar derivatives (Colaco C.A.L.S., Smith C.J.S., Sen S., Roser D.H., Newman Y., Ring S. and Roser B J. Chemistry of protein stabilisation by trehalose in Formulation and delivery of proteins and peptides Cleland and Langer eds American Chemical Society Washington 222-240 (1994)), it was shown that mannitol and sorbitol were very poor stabilisers. Indeed in several patent applications it has been claimed that mannitol and certain other monosaccharide alcohols cannot stabilise at all. PCT No WO 91/18091 "Stabilisation of biological macro-molecular substances and other organic compounds", Roser B.J. and Colaco C claimed that only non-reducing glycosides of a polyhydroxy sugar alcohol or other straight chain polyalcohol or raffinose, stachyose or melezitose were effective in achieving stability, especially on storage. This patent states "Thus the monosaccharide sugar alcohols galactitol, mannitol and erythritol are not satisfactory protective agents". US patent Number 5,621,094 "Method of Preserving Agarose Gel Structure During Dehydration by Adding a Non-reducing Glycoside of a Straight Chain Sugar Alcohol" by Roser B. and Colaco C states that "glucose mannitol and sorbitol failed after one week" while "lactitol and trehalose were perfect after >12 weeks". It further defined effective formulations as "wherein the non-reducing glycoside of a straight chain sugar alcohol does not form crystals during dehydration". PCT No WO 96/05809 "Improved method for stabilisation of biological substances during drying and subsequent storage and compositions thereof, by Colaco C, Roser B.J. and Sen S. claims methods wherein even reducing sugars are used to stabilise products. This is achieved by preventing the sugars from attacking the product by using Maillard reaction inhibitors. This application states that mannitol has no stabilising effect whatsoever.
We have now found this to be incorrect. In contradiction to the statements in these documents we have found that certain monosaccharide sugar alcohols such as mannitol and inositol can be excellent stabilisers when correctly formulated and in fact have significant advantages over trehalose for some applications. In view of mannitol 's acceptance by regulatory authorities and widespread use in the healthcare industry in both parenteral and oral formulations, it has considerable advantages as a new stabilising excipient. Its low cost and chemical inertness, together with its exceptional stability and its high purity and safety, would make it the stabiliser of choice for pharmaceuticals. We have found that certain substances must be present in a formulation to convert mannitol into an excellent stabiliser. The effect of these substances is dose dependent and below a threshold concentration they do not work. The substances useful in accordance with this invention promote the drying of mannitol solutions as glasses rather than crystals. One of the most potent materials is the borate ion either as boric acid, or tetraborate salts of sodium or potassium. This probably forms a network complex with mannitol or even a covalent compound, sodium mannitoborate. Subsequent to the filing of this application containing the disclosure of the surprising efficacy of small amounts of borate in inducing glass formation in drying mannitol solutions, similar beneficial effects with borate and trehalose were reported by Miller et al. Notably, the molar ratio of borate to trehalose used by these authors was considerably higher than we found to be necessary. (Miller DP, Anderson RE and de Pablo JJ. Stabilisation of lactate dehydrogenase following freeze- thawing and vacuum-drying in the presence of trehalose and borate. Pharmaceutical Research 15 1215-1221 (1998)). Other effective materials such as calcium lactate, and proteins such as serum albumin or gelatin, or polyamine materials such as polyvinyl pyrollidone, or polyvinyl alcohol, intrinsically form glasses themselves when dried from solution. Yet other effective chemicals such as acetate salts, will form glasses but only when quenched from the melt and only when the melt contains several metal cations rather than a single cation, such as sodium and calcium. An additional property of the materials identified to date is that the beneficial actions of these materials are additive so that they can be mixed together in successful formulations which contain sub-threshold doses of each additive alone. Other substances which are either themselves glass-formers (under certain conditions) or are glass-formation-facilitators such as the phosphate salts of sodium and potassium and sodium silicate are capable of being utilised to make stabilising glasses according to this invention.
The quality of the glasses made by this process is high. The glass transition temperature (Tg) of 1 :1 w/w mannitol/calcium lactate glass is around 68°C (Figure 1). This compares with a Tg of around 90°C for a trehalose/sodium sulphate glass dried under the same conditions (Figure 2). Both types of glass have Tg's well above any possible ambient storage temperature and, because the glasses are chemically inert and non-reactive, the entrapped products are stable at room temperatures and require no refrigeration of any kind. It is a particular advantage of this invention that sugars \\ Inch have pre\ lously been known as stabilisers in methods of freeze drying may be used successfully in drying compounds subject to deactivation on drying whilst utilising drying temperatures above freezing point (e g. room temperature or above) Thus US Patent 5,589,167 "Excipient stabilisation of polypeptides treated λ\ ith organic solvents" by Cleland and Jones reports that mannitol and trehalose are both excellent stabilisers for the recombinant peptides human Growth Hormone and human Interferon gamma on freeze-drying and on exposure to organic solvents. These authors found that the ratio of active to excipient was cπtical in achieving the optimum stabilisation Without wishing to be bound by theory, it is likely that the good results reported in this patent are not so much due to the substitution of freeze-drymg for ambient temperature drying but the use of very high ratios of active to excipient m the formulations Under these circumstances, where the mass ratio of peptide to mannitol or trehalose was 1 to 1 or higher, the peptide itself was acting as an enhancer of glass transformation of the drying sugar solutions in a manner analogous to the action of albumin or gelatin shown below. A seπous disadvantage of this approach is that highly potent drugs and vaccines need tiny amounts of stabilising sugars to give a good stabilising glass. Single dose ampoules for example appear to be completely empty; the thin film of dried product being invisible in the container This is confusing to the end user and can be wasteful, if the container is discarded in error, or even dangerous, if the time to complete dissolution of the product is not obvious after reconstitution This greatly reduces the flexibility of formulation and presentation of the product
What is required is a robust formulation that inherently forms a good glass even in the absence of product but which can accommodate a wide range of product concentrations without loss of glass forming capacity and stabilising efficacy A number of sugar alcohols previously rejected as stabilising agents in the prior art listed above such as mannitol, xylitol, mositol, arabmitol and galactitol stabilise very effectively when correctly formulated so as to promote the formation of a glassy matrix, rather than crystals, on drying. A simple method for inhibiting crystallisation is to mix two or more sugars or sugar derivatives together in the same formulation When correctly chosen, these mutually inhibit crystallisation and the mixture dπes as an amorphous glass. In some cases these glasses are more robust on storage and give greater stability to an included product than trehalose itself Brief Description of the Figures
Figure 1 shows differential scanning calorimetry of a 50 / 50 w/w mannitol / calcium lactate glass showing a clear glass transition at a temperature of 68 °C;
Figure 2 shows differential scanning calorimetry of a 50 / 50 w/w trehalose / calcium lactate glass showing a clear glass transition at a temperature of 90 °C;
Figure 3 shows the percentage recovery of alkaline phosphatase activity after vacuum- drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 6 weeks. There is no loss with formula 7 but serious losses with trehalose;
Figure 4 shows the percentage recovery of alkaline phosphatase activity after freeze-drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 7 weeks. There is little loss with either stabiliser;
Figure 5 shows the percentage recovery of Erythropoietin (EPO) after vacuum-drying in either trehalose or formula 8 containing mannitol, inositol, galactitol and calcium lactate followed by storage at 37°C or 50°C for up to 6 weeks. While there is serious losses with trehalose, no loss occurs with formula 8; and
Figure 6 shows the percentage recovery of EPO after freeze-drying in either trehalose or formula 7 containing mannitol, Inositol, galactitol and degraded gelatin (Byco C) or formula 8 in which calcium lactate was substituted for the gelatin. After storage at 37°C or 50°C for 7 weeks, there is no loss with any of the stabilising formulations.
Figure 7 shows the percentage recovery of alkaline phosphatase activity after spray drying formula 9 to which had been added insoluble calcium phosphate powder to increase the density of the glass microspheres. After storage at either 37°C or 55°C for up to 90 days there was no significant loss of activity. Figure 8 shows the percentage recovery alkaline phosphatase activity after spray drying formula 1 1 to which had been added insoluble barium sulphate powder to increase the density of the glass microspheres. After storage at either 37"C or 55°C for up to 90 days there was again no significant loss of activity.
Examples
Example 1
A solution of mannitol in water 20% w/v was pipetted in 100 μl volumes on to the surface of clean glass microscope slides which were laid flat on a hotplate at 70°C for drying. Within about 5 min. the solution had dried into a mass of crystals. A 20% solution of trehalose or palatinit, dried under the same conditions formed a hard and transparent perfect glass film. Only the latter sugars stabilise actives successfully as described in the patents and publications referenced above. This is considered to be a function of their ability to form amorphous glass on drying.
The addition of a network forming additive such as sodium or potassium tetraborate to the mannitol solution in amounts of less than 10% of the weight of mannitol, completely inhibited crystallisation on drying and resulted in the formation of glasses as perfect as those made with trehalose or palatinit. This demonstrated that mannitol can form glasses under appropriate conditions and a search was then made for less toxic additives to achieve the same effect.
Example 2
Equal weights of trehalose or palatinit were mixed with the mannitol in solution and dried as above. In both cases this yielded perfect glasses showing that these two glass-forming sugars could inhibit the crystallisation of mannitol. Even a sugar which was not itself a glass former, such as galactitol, inhibited the crystallisation of a mannitol / inositol mixture which itself crystallised readily. Similar results were found when equal weights of other glass forming substances such as calcium lactate, albumin, polyvinyl pyrollidone or degraded gelatin (Byco C) were added to mannitol in solution. To establish the longer term stability of these glasses they were held at 70°C overnight and then at room temperature and ambient humidity for several weeks and inspected frequently. All the above glasses were stable under both sets of conditions. When other monosaccharide alcohols such as galactitol, xylitol. arabinitol, adonitol, or inositol were substituted for mannitol. similar results were obtained but the resulting glasses were very soft when alcohols of the pentose sugars were used.
Example 3
More complex mixtures of the monosaccharide alcohols could also be blended together with glass forming substances to yield excellent glasses, which showed good physical stability in the glass phase at 70°C and at ambient conditions for many weeks as described in Example 2. Some good formulations are:-
1. mannitol 33.3%, inositol 33.3% and PVP 33.3%
2. mannitol 31.6%, inositol 31.6% xylitol 5% and calcium lactate 31.6%
3. mannitol 33.3%, inositol 33.3% and calcium lactate 33.3%
4. mannitol 33.3%, inositol 33.3% and Byco C 33.3%
5. mannitol 23.3%, inositol 23.3% calcium lactate 30% and PVP 23.3%
6. mannitol 33.3%), arabinitol 33.3%o and calcium lactate 33.3%
7. mannitol 30%, inositol 15% galactitol 15% and Byco C 40%
8. mannitol 30%, inositol 15% galactitol 15% and calcium lactate 40%
9. mannitol 33%, Byco C 33% and calcium lactate 33%
10. mannitol 50%, and Kollidon 30 (polyvinylpyrollidone (PVP)) 50%
11. mannitol 33%, Kollidon 30 (polyvinylpyrollidone (PVP)) 33% and calcium lactate 33%
12. mannitol 50%, and Dextran 50%
13. mannitol 33%, Dextran 33% and calcium lactate 33%
In short, simple trial and error experimentation will establish a successful formulation from mixtures of monosaccharide alcohols and a glass forming substance. By this method the final concentration of any single ingredient can be kept low. In this way a substantial total solids content can be achieved, even including sugar alcohols, which are individually not very soluble. The high solids content shortens drying times and increases the protection of the active during drying.
In addition to heat-assisted air-drying as above, formulations of this kind have been successfully vacuum dried, spray dried and freeze-dried. Example 4
Stability of alkaline phosphatase enzyme
Affinity purified alkaline phosphatase from bovme intestinal mucosa (Sigma Chemical Co cat No p-8647) was vacuum-dπed or freeze-dπed m 200 μl volumes in formulation Number 7 above or in trehalose. and stored at 37°C or 50°C for 5 weeks Samples were tested for activity at intervals using the Sigma assay with p-nitrophenyl phosphate as substrate Vacuum drying was done at a shelf temperature of 40°C and a vacuum of 30- 100 milhtorr for 4 hr The temperature was then ramped gradually to 60°C over 1 hr and the vials were stoppered and removed from the vacuum chamber for high temperature storage trials Freeze-drying was done in a Labconco dryer at an initial shelf temperature of-40°C for 3 hr at a vacuum of 30-100 milhtorr The shelf temperature was then ramped to 0°C at 5°C / mm and held for 1 hr The shelf temperature was then raised to 40°C at 5°C / min and secondary drying was continued for a further 3 hr when the vials were stoppered under vacuum and removed for storage trials
While there was some variability in the assays of enzyme activity, obvious trends were observed Samples dried by either method without stabilisers lost all activity withm a day or two of storage (not shown) Samples dried in either mannitol alone or a modified formula 7 lacking the glass forming facilitator lost between 75 and 80%> of activity within 3 days at 37°C
There was also a progressive loss of enzyme activity seen with the samples vacuum-dπed in trehalose, which was not seen m the samples dπed in formula 7 (Fig 3) This was particularly marked where the samples had been stored at the higher temperature (50°C) No such loss in the trehalose-dπed samples was seen in the freeze-drying experiments where trehalose appeared to be slightly superior to the monosaccharide alcohols (Fig 4) This result might possibly indicate that a higher residual moisture content may have been responsible for the seπous losses with trehalose in the vacuum dπed samples Whatever the explanation, it is clear that formula 7 gives results which are equivalent to, or supeπor to, the results obtained with trehalose Example 5
Stability of lecombmant human Erythropoietin (EPO)
EPO was vacuum dried or freeze-dπed as above in the same solutions and also in a vaπant of formulation 7 in which calcium lactate was substituted for Byco C (Formula 8), and then subjected to the same stability tests before being assayed by a standard 2-sιte sandwich Enzyme Immunoassay
The results again showed a serious, progressive deterioration in the vacuum dπed samples dπed in trehalose, more dramatic at 50°C storage temperature, which was not seen with the samples dπed in formula 8 (fig 5) The deterioration in trehalose was not seen m the freeze-dπed samples stored at 37°C (not shown) or 50°C (Fig 6) Irrespective of whether formula 7 or 8 was used, all samples showed essentially complete recovery of activity
Example 6
The fluorescent protein R-Phycoerythπn was air-dried in trehalose, formula 3 or formula 4 on a hotplate as described in Example 1 The intensity of fluorescence was gauged visually when illuminated with a UV lamp. In the controls dried in trehalose fluorescence was retained The material dried in formula 3 was masked by an intense silver autofluorescence from the Byco C while the material dried in formula 4 fluoresced with the characteristic orange colour with apparently undimmished intensity

Claims

Claims
1. A method of drying, without damage, a compound which is subject to deactivation on drying, or a mixture of such compounds, comprising subjecting an aqueous system containing the compound or mixture to drying in the presence of one or more monosaccharide sugar alcohols and at least one additive which is a glass-former or a glass- formation-facilitator, whereby the compound solidifies from solution as an amorphous glass rather than by forming crystals.
2. A method according to claim 1 in which the aqueous system contains from 0.05 to 90%) by weight of sugar alcohol.
3. A method according to claim 1 in which the ratio of sugar alcohol plus additive to compound is at least 0.25: 1 preferably 0.5: 1 by weight.
4. A method according to any of claim 1 to 3 in which the compound is a protein, polysaccharide or nucleic acid.
5. A method according to claim 4 in which the compound or mixture comprises an enzyme, serum, serum complement, an antibody or antigen (either free or coupled to a support), a nucleic acid, a fluorescent protein, or a vaccine component.
6. A method according to any of claim 1 to 5 in which the system is dried under conditions selected from one or more of the group consisting of ambient temperature or above, chill drying, freeze drying, spray drying, vacuum drying and drying at atmospheric pressure.
7. A dried product which is an amorphous glass containing monosaccharide sugar alcohol and at least one additive which is a glass-former or a glass-formation-facilitator and a compound which is subject to deactivation on drying, or a mixture of such compounds, in a weight ratio of sugar alcohol plus additive to compound of at least 0.25:1 preferably 0.5:1, the product having been dried.
8. A dried product according to claim 7 in which the compound is a protein, polysaccharide or nucleic acid.
9. A dried product according to claim 8 containing an enzyme, serum complement, an antibody or antigen (either free or coupled to a support), a nucleic acid, a fluorescent protein, or a vaccine component.
10. A method or product according to any preceding claim wherein the sugar alcohol is selected from the group consisting of mannitol, galactitol, xylitol, arabinitol and inositol.
11. A method or product according to any preceding claim wherein there is one or a mixture of additives selected from the group consisting of peptide, protein, borate ion, calcium lactate, phosphate, silicate and acetate salts.
12. A method or product according to claim 11 wherein at least one additive is selected from the group consisting of boric acid, tetraborate salt of sodium or potassium and sodium mannitoborate.
13. A method or product according to any preceding claim wherein the amorphous glass is formed from a mixture of 2 or more monosaccharide sugar alcohols.
14. A method or product according to any preceding claim wherein there is an additive which is a protein or denatured protein.
15. A method or product according to claim 1 or 7 wherein the amorphous glass is formed from a formulation having essentially a composition selected from:
1. mannitol 33.3%, inositol 33.3% and PVP 33.3%
2. mannitol 31.6%>, inositol 31.6%> xylitol 5%> and calcium lactate 31.6%
3. mannitol 33.3%, inositol 33.3% and calcium lactate 33.3%
4. mannitol 33.3%, inositol 33.3% and Byco C 33.3%
5. mannitol 23.3%, inositol 23.3% calcium lactate 30% and PVP 23.3%
6. mannitol 33.3%, arabinitol 33.3% and calcium lactate 33.3%
7. mannitol 30%, inositol 15% galactitol 15% and Byco C 40%)
8. mannitol 30%, inositol 15% galactitol 15% and calcium lactate 40%>
9. mannitol 33%o, Byco C 33% and calcium lactate 33%
10. mannitol 50%, and Kollidon 30 (polyvinylpyrollidone (PVP)) 50%
11. mannitol 33%, Kollidon 30 (polyvinylpyrollidone (PVP)) 33%o and calcium lactate 33%
12. mannitol 50%, and Dextran 50%
13. mannitol 33%, Dextran 33% and calcium lactate 33%
PCT/GB1999/000820 1998-03-18 1999-03-17 Amorphous glasses for stabilising sensitive products WO1999047174A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29451/99A AU2945199A (en) 1998-03-18 1999-03-17 Amorphous glasses for stabilising sensitive products
EP99910516A EP1071465A1 (en) 1998-03-18 1999-03-17 Amorphous glasses for stabilising sensitive products

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9805699.7 1998-03-18
GBGB9805699.7A GB9805699D0 (en) 1998-03-18 1998-03-18 New stabilising glasses
GBGB9820689.9A GB9820689D0 (en) 1998-09-23 1998-09-23 New stabilising glasses
GB9820689.9 1998-09-23

Publications (1)

Publication Number Publication Date
WO1999047174A1 true WO1999047174A1 (en) 1999-09-23

Family

ID=26313295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000820 WO1999047174A1 (en) 1998-03-18 1999-03-17 Amorphous glasses for stabilising sensitive products

Country Status (3)

Country Link
EP (1) EP1071465A1 (en)
AU (1) AU2945199A (en)
WO (1) WO1999047174A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
WO2001089313A1 (en) * 2000-05-26 2001-11-29 British Sugar Plc Edible products with coatings comprising amorphous trehalose
US6623762B2 (en) 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1449523A1 (en) * 2000-10-13 2004-08-25 Cambridge Biostability Ltd Composition and method for stable injectable liquids
US20080294100A1 (en) * 2005-11-21 2008-11-27 Cambridge Biostability Limited Pharmaceutical Device For the Administration of Substrates to Patients
EP2290366A1 (en) 2004-03-17 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Analysis of saccharide vaccines without interference
WO2011048379A2 (en) 2009-10-21 2011-04-28 Innovata Limited Composition
CN107340387A (en) * 2017-06-20 2017-11-10 广东云天抗体生物科技有限公司 A kind of preparation method of cell factor ELISA standard items
IT201900025063A1 (en) * 2019-12-20 2021-06-20 Idi Integratori Dietetici Italiani S R L GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112538111B (en) * 2020-12-09 2022-04-29 深圳市亚辉龙生物科技股份有限公司 New coronavirus single-chain antibody, quality control product and preparation method

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806524A (en) * 1984-10-18 1989-02-21 Chugai Seiyaku Kabushiki Kaisha Stable erythropoietin preparation and process for formulating the same
EP0682944A1 (en) * 1994-05-04 1995-11-22 Sanofi Stable lyophilized formulation containing a protein and dosage kit
WO1996005809A1 (en) * 1994-08-19 1996-02-29 Quadrant Holdings Cambridge Limited Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
WO1998041188A2 (en) * 1997-03-18 1998-09-24 Quadrant Holdings Cambridge Limited Stable particle in liquid formulations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806524A (en) * 1984-10-18 1989-02-21 Chugai Seiyaku Kabushiki Kaisha Stable erythropoietin preparation and process for formulating the same
US5621094A (en) * 1990-05-14 1997-04-15 Quadrant Holdings Cambridge Limited Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
EP0682944A1 (en) * 1994-05-04 1995-11-22 Sanofi Stable lyophilized formulation containing a protein and dosage kit
WO1996005809A1 (en) * 1994-08-19 1996-02-29 Quadrant Holdings Cambridge Limited Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1996040077A2 (en) * 1995-06-07 1996-12-19 Quadrant Holdings Cambridge Limited Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby
WO1998041188A2 (en) * 1997-03-18 1998-09-24 Quadrant Holdings Cambridge Limited Stable particle in liquid formulations

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190701B1 (en) 1999-03-17 2001-02-20 Peter M. Ronai Composition and method for stable injectable liquids
WO2001089313A1 (en) * 2000-05-26 2001-11-29 British Sugar Plc Edible products with coatings comprising amorphous trehalose
US6919172B2 (en) 2000-07-26 2005-07-19 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
EP1449523A1 (en) * 2000-10-13 2004-08-25 Cambridge Biostability Ltd Composition and method for stable injectable liquids
EP1452171A2 (en) * 2000-10-13 2004-09-01 Cambridge Biostability Ltd Pharmaceutical liquid suspensions
EP1452171A3 (en) * 2000-10-13 2004-11-10 Cambridge Biostability Ltd Pharmaceutical liquid suspensions
KR100852389B1 (en) 2001-02-16 2008-08-14 캠브리지 바이오스테빌리티 리미티드 Composition and method for controlled release injections
US6623762B2 (en) 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
EP2290366A1 (en) 2004-03-17 2011-03-02 Novartis Vaccines and Diagnostics S.r.l. Analysis of saccharide vaccines without interference
US20080294100A1 (en) * 2005-11-21 2008-11-27 Cambridge Biostability Limited Pharmaceutical Device For the Administration of Substrates to Patients
US8821437B2 (en) * 2005-11-21 2014-09-02 Nova Bio-Pharma Technologies Limited Pharmaceutical device for the administration of substances to patients
WO2011048379A2 (en) 2009-10-21 2011-04-28 Innovata Limited Composition
CN107340387A (en) * 2017-06-20 2017-11-10 广东云天抗体生物科技有限公司 A kind of preparation method of cell factor ELISA standard items
IT201900025063A1 (en) * 2019-12-20 2021-06-20 Idi Integratori Dietetici Italiani S R L GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE
WO2021124244A1 (en) * 2019-12-20 2021-06-24 Idi Integratori Dietetici Italiani S.R.L. Gastro-resistant microparticles comprising inositol and/or gymnema sylvestre extract, pharmaceutical and nutraceutical compositions thereof and uses thereof

Also Published As

Publication number Publication date
AU2945199A (en) 1999-10-11
EP1071465A1 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
KR100777349B1 (en) Preservation of Sensitive Biological Material
Izutsu et al. Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices
EP1071465A1 (en) Amorphous glasses for stabilising sensitive products
US6669963B1 (en) Stable particle in liquid formulations
RU2191003C2 (en) Composition and method of stabilization of biological materials by drying without freezing
EP0541556B1 (en) Stabilization of biological macromolecular substances and other organic compounds
US6313102B1 (en) Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
US7153472B1 (en) Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
WO1996033744A2 (en) Compositions in glassy phase, stabilised by a sugar
EP2222315B1 (en) Stabilized factor ix formulations containing trehalose
Iglesias et al. Adsorption isotherm of amorphous trehalose
EP2552410B1 (en) Method for preserving alum adjuvants and alum-adjuvanted vaccines
EP0415567A2 (en) Composition and method for stabilising organic compounds
Jangle et al. Vacuum foam drying: an alternative to lyophilization for biomolecule preservation
Pisal et al. Vacuum foam drying for preservation of LaSota virus: effect of additives
US7101693B2 (en) Plasticized hydrophilic glasses for improved stabilization of biological agents
NZ264861A (en) Freeze-dried thiotepa (1,1',1"-phosphinothioylidyne tris aziridine) prepared by freeze drying a solution of thiotepa which has a ph of 7-9
AU4392899A (en) Water soluble dry compositions
US20230144557A1 (en) Method of long-term preservation of chemical and biological species using sugar glasses
CN101991857B (en) Stable pharmaceutical preparation and preparation method thereof
EP1254944B1 (en) Dry compositions containing hydrophobic amino acid
EP0169700B1 (en) Improved pharmaceutical formulations for ceftazidime
Hajare et al. Foam dried composite glass: An alternative to lyophilization for stability enhancement of bendamustine hydrochloride
US4626534A (en) Pharmaceutical formulation
Hajare Ashok et al. Foam Dried Composite Glass: An alternative to Lyophilization for Stability Enhancement of Bendamustine Hydrochloride

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999910516

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09623495

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999910516

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999910516

Country of ref document: EP